Degens J, De Ruysscher D, Houben R, et al. - In this retrospective multicentre cohort study, researchers analyzed patients with stage III non-small cell lung cancer (NSCLC) managed with chemoradiotherapy (CRT) in order to determine the incidence of new cardiac events within 5 years post-diagnosis using a common terminology criteria for adverse events (CTCAE) score of ≥ 2. In addition, they assessed risk factors related to the occurrence of a cardiac event. This study involved 460 patients, of whom 150 (32.6%) developed a new cardiac event. Arrhythmia (14.6%), heart failure (7.6%) and symptomatic coronary artery disease (6.8%) were reported as the most common cardiac events. Factors significantly related to encountering a cardiac event were pre-existent cardiac comorbidity and WHO-performance score ≥2. As per findings, development of a new cardiac event within 5 years post-CRT was found in one-third of patients with stage III NSCLC treated in daily clinical practice. Based on these data, all physicians dealing with patients with NSCLC are recommended to view cardiac comorbidity as a likely explanation for dyspnea following treatment with CRT.